AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

Fintel reports that on December 11, 2024, HC Wainwright & Co. downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...

TD Cowen analyst Joseph Thome maintained a Buy rating on AnaptysBio (ANAB – Research Report) today. The company’s shares opened today at ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

AnaptysBio, Inc. has a 1-year low of $15.78 and a 1-year high of $41.31. AnaptysBio ( NASDAQ:ANAB – Get Free Report ) last posted its quarterly earnings results on Tuesday, November 5th.

The company had been nominally out in front among developers of Tim3-targeted drugs, slightly ahead of GSK and partner AnaptysBio with cobolimab, which is being tested alongside GSK’s PD-1 ...